Biosig Instruments, Inc. v. Nautilus, Inc.

715 F.3d 891, 106 U.S.P.Q. 2d (BNA) 1554, 2013 WL 1776745, 2013 U.S. App. LEXIS 8486
CourtCourt of Appeals for the Federal Circuit
DecidedApril 26, 2013
Docket2012-1289
StatusPublished
Cited by15 cases

This text of 715 F.3d 891 (Biosig Instruments, Inc. v. Nautilus, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Biosig Instruments, Inc. v. Nautilus, Inc., 715 F.3d 891, 106 U.S.P.Q. 2d (BNA) 1554, 2013 WL 1776745, 2013 U.S. App. LEXIS 8486 (Fed. Cir. 2013).

Opinions

Opinion for the court filed by Circuit Judge WALLACH. Concurring opinion filed by Circuit Judge SCHALL.

WALLACH, Circuit Judge.

Biosig Instruments, Inc. (“Biosig”) is the assignee of U.S. Patent No. 5,337,753 (“the '753 patent”), which is directed to a heart rate monitor associated with an exercise apparatus and/or exercise procedures. Biosig brought a patent infringement action against Nautilus, Inc. (“Nautilus”) in district court alleging that Nautilus infringed claims 1 and 11 of the '753 patent. After claim construction, Nautilus filed a motion for summary judgment seeking, in relevant portion, to have the '753 patent held invalid for indefiniteness. The district court granted Nautilus’s motion, and Biosig appealed. Because the claims at issue are not invalid for indefiniteness, the district court’s decision is reversed and remanded for further proceedings.

Background

I.

The '753 patent is directed to a heart rate monitor that purports to improve upon the prior art by effectively eliminating noise signals during the process of detecting a user’s heart rate. '753 patent [894]*894col. 1 ll. 5-10. According to the patent, prior art monitors did not eliminate signals given off by skeletal muscles (“electromyo-gram” or “EMG” signals), which are brought about when users move their arms or squeeze the monitor with their fingers. Id. col. 1 ll. 19-22. Because EMG signals are of the same frequency range as electrical signals generated .by the heart (“electrocardiograph” or “ECG” signals), EMG signals can mask ECG signals rendering heart rate determination while exercising difficult. Id. col. 1 ll. 22-25.-

[[Image here]]

The '753 patent discloses an apparatus preferably mounted on exercise equipment that measures heart rates by, inter alia, processing ECG signals from which EMG signals are substantially removed. Id. col. 1. ll. 36-41. The claimed heart rate monitor consists of an elongate hollow cylindrical member that houses electronic circuitry as illustrated below:

'753 patent fig. 1. A user’s left and right hands-100 and 200-each contact one of the “live” electrodes-9 and 13-and one of the “common” electrodes-11 and 15-on either end of the cylindrical member 3. Id. col. 2 ll. 50-64, col. 3 ll. 26-31. The electronic circuitry includes a difference amplifier 23, which is connected to the live electrodes 9 and 13. Id. col. 3 ll. 7-10. The common electrodes 11 and 15 are connected to each other and to a point of common potential, for example, a common ground. Id. col. 3 ll. 5-7. An illustration of the circuitry is shown below:

'753 patent fig. 2. Inputs 25 and 27 are of opposite polarity. Id. col. 3 ll. 10-13. As the EMG signals and other noise signals are of substantially equal amplitude and [895]*895phase, they cancel each other out in the difference amplifier to provide a substantially zero output of EMG and other noise signals. Id. col. 3 ll. 33-43. In- contrast, ECG signals, being of opposite phase, will be added and therefore further amplified in the difference amplifier so that the output of the difference amplifier is substantially due to the ECG signals only. Id. col. 3 ll. 44-50.

Claim 1 is representative and recites, in relevant part:

1. A heart rate monitor for use by a user in association with exercise apparatus and/or exercise procedures, comprising:
an elongate member;
electronic circuitry including a difference amplifier having a- first input terminal of a first polarity and a second input terminal of a second polarity opposite to said first polarity;
said elongate member comprising a first half and a second half;
a first live electrode and a first common electrode mounted on said first half in spaced relationship with each other;
a second live electrode and a second common electrode mounted on said second half in spaced relationship with each other;
said first and second common electrodes being connected to each other and to a point of common potential....

'753 patent col. 5 ll. 17-36 (emphases added). In addition to the capability of substantially removing EMG signals, claim 1 recites a monitor, a means for measuring time intervals between heart pulses, and a means for calculating the heart rate of a user using the measured time intervals. See id. col. 5 1. 37—col. 61.15.

Asserted-dependent claim 11 further specifies that the claimed “elongate member” is “mounted on an exercise apparatus.” Id. col. 7 ll. 17-20. Figures 7 and 8 are illustrative of a heart rate monitor mounted on a bicycle and a stair-climbing exercise machine:

Id. figs. 7-8.

II.

The dispute between the parties has been ongoing for years, stemming from [896]*896the late 1990s when Biosig was in discussions with Nautilus’s predecessor Stairmaster Company regarding Biosig’s patented technology. Despite these discussions, Stairmaster Company, and later Nautilus, began selling exercise equipment that Biosig alleges infringes its patented technology. These accused products consist of heart rate monitors mounted on exercise equipment.

Biosig sued Nautilus for infringing the '753 patent in August 2004 (“2004 Action”). During the pendency of that litigation, Nautilus twice sought ex parte reexamination of the '753 patent from the United States Patent and Trademark Office (“PTO”). The first reexamination request was based primarily on U.S. Patent No. 4,444,200 (“Fujisaki”).1 The PTO granted Nautilus’s request, and in April 2009, the PTO issued an office action rejecting, inter alia, claim 1 as anticipated by Fujisaki and claim 11 as obvious over Fujisaki in view of other prior art references. After Biosig filed its response to this PTO office action, Nautilus requested a second reexamination of the '753 patent, again, citing Fujisaki as the primary reference. The PTO granted Nautilus’s second request for reexamination, and the two reexamination proceedings were consolidated in December 2009. The PTO ultimately concluded these reexamination proceedings in June 2010 and confirmed the patentability of the '753 patent without amendment. During the pen-dency of this reexamination proceeding, the parties voluntarily dismissed without prejudice the claims and counterclaims of the 2004 Action.

Upon conclusion of the reexamination proceeding, Biosig re-instituted a patent infringement action against Nautilus on October 8, 2010.- On August 11, 2011, the district court conducted a Markman hearing, and on September 29, 2011, issued its order construing certain disputed claim terms.2 On November 10, 2011, Nautilus moved under Federal Rule of Civil Procedure 56 seeking summary judgment on two issues: infringement and invalidity for indefiniteness.

On February 22,'2012, the district court held a hearing on Nautilus’s motion for [897]*897summary judgment. As to the issue of infringement, the district court denied Nautilus’s motion as premature because the parties had yet to undertake significant discovery. Summ. J. Hr’g Tr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Boston Scientific Corp. v. Cook Inc.
187 F. Supp. 3d 249 (D. Massachusetts, 2016)
Biosig Instruments, Inc. v. Nautilus, Inc.
783 F.3d 1374 (Federal Circuit, 2015)
California Institute of Technology v. Hughes Communications Inc.
35 F. Supp. 3d 1176 (C.D. California, 2014)
Broussard v. Go-Devil Manufacturing Co. of LA., Inc.
29 F. Supp. 3d 753 (M.D. Louisiana, 2014)
Nautilus, Inc. v. Biosig Instruments, Inc.
134 S. Ct. 2120 (Supreme Court, 2014)
Inre: Packard
751 F.3d 1307 (Federal Circuit, 2014)
EON Corp IP Holdings LLC v. Aruba Networks Inc.
62 F. Supp. 3d 942 (N.D. California, 2014)
H-W Technology, LC v. Overstock.com. Inc.
973 F. Supp. 2d 689 (N.D. Texas, 2013)
Apotex, Inc. v. UCB, Inc.
970 F. Supp. 2d 1297 (S.D. Florida, 2013)
Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.
723 F.3d 1363 (Federal Circuit, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
715 F.3d 891, 106 U.S.P.Q. 2d (BNA) 1554, 2013 WL 1776745, 2013 U.S. App. LEXIS 8486, Counsel Stack Legal Research, https://law.counselstack.com/opinion/biosig-instruments-inc-v-nautilus-inc-cafc-2013.